Effect of serum and C-apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase
about
Human apolipoprotein C-I accounts for the ability of plasma high density lipoproteins to inhibit the cholesteryl ester transfer protein activityTranscriptional regulation of apolipoprotein C-III gene expression by the orphan nuclear receptor RORalphaApolipoprotein C-III(Lys58----Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemiaMetabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteinsHeavy marijuana users show increased serum apolipoprotein C-III levels: evidence from proteomic analysesApolipoprotein C3 gene variants and the risk of coronary heart disease: A meta-analysisNew Era of Lipid-Lowering DrugsPrimary structure of the bovine analogues to human apolipoproteins CII and CIII. Studies on isoforms and evidence for proteolytic processingANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipaseRole of the liver in the degradation of very low density lipoproteins: a study of lipolysis by heparin releasable liver lipase and uptake during isolated rat liver perfusionA decreased expression of angiopoietin-like 3 is protective against atherosclerosis in apoE-deficient miceAPOC1 T45S polymorphism is associated with reduced obesity indices and lower plasma concentrations of leptin and apolipoprotein C-I in aboriginal CanadiansComplexities of plasma apolipoprotein C-III metabolismTherapeutic considerations for postprandial dyslipidaemia.Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivoBiochemical and functional characterization of charge-defined subfractions of high-density lipoprotein from normal adults.Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease.Constitutive inhibition of plasma CETP by apolipoprotein C1 is blunted in dyslipidemic patients with coronary artery disease.Effect of Hypertriglyceridemia on Beta Cell Mass and Function in ApoC3 Transgenic Mice.PPAR{alpha} mediates the hypolipidemic action of fibrates by antagonizing FoxO1ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan.Development of Antisense Drugs for Dyslipidemia.Overexpression of apolipoprotein C-III decreases secretion of dietary triglyceride into lymphLipid disturbances in psoriasis: an update.The relationship between high density lipoprotein subclass profile and apolipoprotein concentrations.Genetics of coronary heart disease: towards causal mechanisms, novel drug targets and more personalized prevention.Foxo1 mediates insulin action on apoC-III and triglyceride metabolism.Apolipoprotein C-I binds more strongly to phospholipid/triolein/water than triolein/water interfaces: a possible model for inhibiting cholesterol ester transfer protein activity and triacylglycerol-rich lipoprotein uptake.Intralipid administration induces a lipoprotein lipase-like activity in the livers of starved adult rats.Plasma kinetics of VLDL and HDL apoC-I in normolipidemic and hypertriglyceridemic subjects.Plasma apolipoprotein CI protects against mortality from infection in old age.Overexpression of apoC-I in apoE-null mice: severe hypertriglyceridemia due to inhibition of hepatic lipase.Plasma turnover of HDL apoC-I, apoC-III, and apoE in humans: in vivo evidence for a link between HDL apoC-III and apoA-I metabolism.A high-carbohydrate diet enhances the adverse effect of the S2 allele of APOC3 SstI polymorphism on the TG/HDL-C ratio only in young Chinese females.APOC3 Protein Is Not a Predisposing Factor for Fat-induced Nonalcoholic Fatty Liver Disease in Mice.Effect of hepatic insulin expression on lipid metabolism in diabetic mice.The hepatic heparin releasable lipase binds to high density lipoproteins.
P2860
00eaa025ec1878fc0734e1ade82a7eb227a694fc29199e6493fa8da91bd4f9fea39776a699a782072a841c0cd0502c9e0e1381bdd3135bd22583bd687911760d64c30f55ad743d77c28c196fdf17f1279651ad0098973848f006512276889f83b634fceca6a9287fe1ab924bb54b830d7e4f98930031cd13afd2c6758b7d2c309dec7e0d57c5c1e80b1770b0be44f5d0a25b7900fe4ed536c06491fd38887ef0c10262f749565666fb0e30bf6c1fd1a4f5bde64dc38d19c21852d478028e6e55c180466fa72814f9d852804106985d0eb4ce6015954a0fc2a37573d7e6f609fde0c4bb82a3a68ead5dc2fe713200c598
P248
Q24290207-EA3703CE-A635-4254-B32D-3A5A00664578Q24290442-B5C34CD4-A287-4073-9376-62773BDD6831Q24633209-1F570387-7820-45A5-85DE-04379BCE4499Q24651503-21C0CD63-2D84-4753-8CC6-82F4C5BF16D6Q24654726-59D0F9B2-0E50-43A6-9658-EFD96F29F094Q26743466-11AFC7AB-D24D-4694-ACDF-00B9418F7456Q28072298-BC225523-8D3F-4F51-9C7B-0AD4BFA73D38Q28253353-24EF5410-3824-4800-BF95-E47E9D9EC844Q28505778-B33B3EE7-7128-4952-A2AE-490042FBB607Q28576599-7D8BFEF4-4860-4096-8881-03A97E77D993Q28589301-B7247A5A-A3B1-4721-828C-CCC7433B4CAEQ33741245-CB943536-B6D6-4E6D-94A2-16D00A1813D0Q34172178-EC0212AD-9F55-40DD-8BDB-3D82EAA393B9Q34285956-F6EE2C26-4D4D-46F1-8066-CD6CF45339D1Q34546130-22684CC6-68F8-4ADF-BE53-1BD8504091AAQ35028691-9C789FAA-6A36-406F-9718-83CDBA2DB9E2Q35915137-26D615BF-F06D-4904-B3A7-004A36CF246EQ35958497-0CD57355-6479-4D88-A794-4D605D1698CDQ37078689-B9D612B0-C2FC-4D15-938D-9D583A419C88Q37149423-E698A16D-C825-4DD2-9506-3AA92771B210Q37317424-A9C462D9-46D5-4F07-A8CD-EA511518BE90Q37387192-15A63EB3-AB0C-4629-84EF-4E66E1894222Q37727877-5498C235-0D1A-4B24-BE5D-06A121442354Q37779736-6DE72684-2A04-42E8-9708-25484BBA6716Q37900093-B12EC341-E5DA-47B9-91D8-C1BF46622C1EQ38610278-FF149803-11D4-44BE-B66F-36BE235EE7C9Q40301333-2EBF131F-8C01-4890-BC2D-A1ED34B8389AQ42114918-72B823F7-9C96-4320-9066-2A19433D0C04Q42853664-4A0AEF33-071E-456D-BB3B-21F21BE1C243Q44168307-092B16F5-7F3C-4A31-890E-D41891574D24Q44179480-2D862F7D-FFFF-41AF-9E0E-7A791F9962AEQ44231224-4A4ECD4C-99BC-411F-B5CE-907892F3CEBFQ44516309-76F9A1A5-BF62-463B-884E-7E7DEA8B1565Q51031956-E23668E2-5780-4C72-BB89-062C6737C4AFQ51172839-16A9910A-A99A-4444-A1D4-2C42A979D115Q53551509-2F76B786-CE62-4231-8608-ECB5D8D01DD7Q54105589-4C8FF72B-6F11-4134-BED4-710B7E6CD9F0
P2860
Effect of serum and C-apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase
description
1976 nî lūn-bûn
@nan
1976 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1976 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1976年の論文
@ja
1976年論文
@yue
1976年論文
@zh-hant
1976年論文
@zh-hk
1976年論文
@zh-mo
1976年論文
@zh-tw
1976年论文
@wuu
name
Effect of serum and C-apoprote ...... theparin plasma hepatic lipase
@ast
Effect of serum and C-apoprote ...... theparin plasma hepatic lipase
@en
Effect of serum and C-apoprote ...... theparin plasma hepatic lipase
@en-gb
Effect of serum and C-apoprote ...... theparin plasma hepatic lipase
@nl
type
label
Effect of serum and C-apoprote ...... theparin plasma hepatic lipase
@ast
Effect of serum and C-apoprote ...... theparin plasma hepatic lipase
@en
Effect of serum and C-apoprote ...... theparin plasma hepatic lipase
@en-gb
Effect of serum and C-apoprote ...... theparin plasma hepatic lipase
@nl
prefLabel
Effect of serum and C-apoprote ...... theparin plasma hepatic lipase
@ast
Effect of serum and C-apoprote ...... theparin plasma hepatic lipase
@en
Effect of serum and C-apoprote ...... theparin plasma hepatic lipase
@en-gb
Effect of serum and C-apoprote ...... theparin plasma hepatic lipase
@nl
P2860
P921
P3181
P1433
P1476
Effect of serum and C-apoprote ...... theparin plasma hepatic lipase
@en
P2093
P K Kinnunen
P2860
P3181
P356
10.1016/0014-5793(76)80145-7
P407
P577
1976-06-15T00:00:00Z